integrated continuous bioprocessing
integrated continuous bioprocessing
Tech Unlocks Sustainable Biopharma Revolution
🌍 A study by Imperial College London suggests that digital tools can help companies understand their environmental impact. 💡 Process sustainability can be challenging to quantify, but model-based tools exist to tackle case studies. 💧 Water consumption in cell cultivation and the use of resins and solvents are major sustainability challenges. ⚙️ Continuous manufacturing and automation are seen as sustainable approaches that can lower costs and environmental impact. 📚 However, technical and regulatory challenges need to be addressed for widespread adoption of these practices.
Revolutionizing Data Integration in Bioprocessing: How AI and Algorithms are Transforming Analysis
📰 Improving Data Integration: Challenges in bioprocessing include fragmented data, but tools like GPT-4 and StabMap help analyze efficiently. 🧬💻🔬
Unlocking Vibrio’s Potential: The Future of Bioprocessing
Converging Roads in Bioprocessing explores the potential of using Vibrio in synthetic biology and bioprocessing. 🦠🧪🔬
Revolutionizing Bioprocessing: Metabolism Enhances Accuracy
📰 Adding metabolism to bioprocessing models improves accuracy & value. Multiscale models provide a mechanistic understanding for better control. 🧪🔬
Revolutionizing Bioprocessing: Streamlining Quality Control
📰 Biopharma companies prioritize bioburden control in continuous bioprocessing to ensure product quality. 🧪 Integrated testing expedites detection and eliminates errors. 👩🔬 User requirements aid in fault detection. 💡 Timely decision-making is crucial. 📊 Managing data and implementing a two-tiered control system are key challenges. 👉 New equipment and automation facilitate in-process bioburden testing.
Unveiling the Secret to Sustainable Bioprocessing!
🌱 The bioprocessing industry is striving for sustainability, but its environmental impact remains uncertain. 🌍 Optimizing processes and reducing waste are key. 🚀
CEO of Généthon Reveals Future of Gene Therapy
🔍 Frédéric Revah, CEO of Généthon, reflects on the past, present, and future of the organization in an interview. 🧬 Généthon was created in 1990 with a focus on gene therapy research for rare genetic diseases. 💡 Revah discusses the challenges of financing development for rare diseases and the need for equity in distribution. 🏭 Généthon is working on improving bioprocessing and reducing the cost of production for gene therapies. 🤝 The organization collaborates with partners in various fields to advance their research. ⚙️ Exciting developments include producing AAV in plants and using artificial intelligence to optimize bioreactors. ❌ The industry faces challenges such as improving the full-to-empty ratio of virus capsids. ❗️ Revah comments on the Pfizer incident and assures that Généthon is closely monitoring safety in their own clinical trial.
Sartorius and Sanofi Revolutionize Drug Manufacturing!
🔬 Sartorius teams up with Sanofi to revolutionize drug manufacturing! 🌍💼 The collaboration aims to improve efficiency and sustainability. 🚀🏭
